EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications

Marius Müller, Nadia Bom Pedersen iD, Vladimir Shalgunov, Andreas Ingemann Jensen iD, Umberto Maria Battisti iD, Matthias Manfred Herth

Medicinal Research Reviews · 2026

DOI: 10.1002/med.70008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Marius Müller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Astatine, Radiopharmaceuticals. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by Danmarks Frie Forskningsfond (1032-00177B)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 ( 211 At) has experienced increased interest due to its favorable decay properties. As a result, various 211 At‐astatination strategies have been developed to address challenges associated with working with this “halogenic metalloid.” This review summarizes efforts to produce and scale 211 At, describes its physicochemical properties, discusses the advantages and disadvantages of using a radionuclide with a half‐life of 7.2 h and outlines procedures for astatinating radiopharmaceuticals. Moreover, a key focus of this review is to rationalize strategies aimed at minimizing in vivo deastatination. A brief overview of on‐going (pre)clinical development with 211 At‐labeled radiopharmaceuticals is provided. Astatinated radiopharmaceuticals will play a pivotal role in cancer management in the near future when challenges related to scalability and in vivo stability have been addressed and clinical studies have shown the benefit of 211 At compared to longer‐lived therapeutic radionuclides.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstatineRadiopharmaceuticalsHumansAnimalsNeoplasms

Stichwörter der Autor:innen

(de)astatinationastatine‐211astatine‐211 radiochemistryastatine‐211 radiopharmaceuticalsradioligand therapy

Substanzen

AstatineRadiopharmaceuticalsAstatine-211

Autor:innen und Institutionen

  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark.
  • Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark.
  • DTU Health Technology, Technical University of Denmark (DTU), Lyngby, Denmark.

ORCID-Profile: Nadia Bom Pedersen, Andreas Ingemann Jensen, Umberto Maria Battisti

Förderung

  • This study was supported by Danmarks Frie Forskningsfond (1032-00177B).

Zitieren

APA

Müller, M., Pedersen, N. B., Shalgunov, V., Jensen, A. I., Battisti, U. M., & Herth, M. M. (2026). Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications. Medicinal Research Reviews. https://doi.org/10.1002/med.70008

Vancouver

Müller M, Pedersen NB, Shalgunov V, Jensen AI, Battisti UM, Herth MM. Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications. Medicinal Research Reviews. 2026. doi:10.1002/med.70008

BibTeX
@article{Mller2026,
  author = {Müller, Marius and Pedersen, Nadia Bom and Shalgunov, Vladimir and Jensen, Andreas Ingemann and Battisti, Umberto Maria and Herth, Matthias Manfred},
  title = {Astatine‐211—Towards In Vivo Stable Astatine‐211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications},
  journal = {Medicinal Research Reviews},
  year = {2026},
  doi = {10.1002/med.70008}
}
Kostenlos starten →